Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Holdings Lifted by GSA Capital Partners LLP

GSA Capital Partners LLP lifted its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 80.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,775,700 shares of the company's stock after buying an additional 792,283 shares during the period. GSA Capital Partners LLP owned 1.42% of Karyopharm Therapeutics worth $1,474,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of KPTI. AQR Capital Management LLC increased its position in Karyopharm Therapeutics by 494.5% during the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company's stock worth $649,000 after purchasing an additional 622,194 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Karyopharm Therapeutics during the second quarter worth approximately $494,000. Acadian Asset Management LLC acquired a new position in Karyopharm Therapeutics during the second quarter worth approximately $167,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Karyopharm Therapeutics during the second quarter worth approximately $143,000. Finally, Exchange Traded Concepts LLC increased its position in shares of Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company's stock worth $182,000 after acquiring an additional 56,613 shares in the last quarter. Institutional investors and hedge funds own 66.44% of the company's stock.

Karyopharm Therapeutics Stock Performance

Shares of KPTI stock traded down $0.01 on Thursday, hitting $0.86. The stock had a trading volume of 196,141 shares, compared to its average volume of 1,255,223. The firm has a market capitalization of $107.69 million, a price-to-earnings ratio of -0.76 and a beta of 0.16. The stock's 50 day moving average is $0.82 and its 200-day moving average is $0.90. Karyopharm Therapeutics Inc. has a 52-week low of $0.62 and a 52-week high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to the consensus estimate of $37.86 million. During the same quarter last year, the company earned ($0.30) earnings per share. Equities analysts expect that Karyopharm Therapeutics Inc. will post -0.94 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Piper Sandler increased their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 6th. Robert W. Baird dropped their price objective on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating for the company in a research report on Wednesday, August 7th. StockNews.com raised shares of Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday. HC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research report on Friday, November 1st. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $3.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $5.00.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).